News and Press Releases
Medera's Sardocor Granted FDA Orphan Drug Designation for DMD-associated Cardiomyopathy Gene Therapy
February 28, 2024
Medera's Sardocor Announces Fast Track Designation and Dosing of 3 Patients in First-in-Human HFpEF Gene Therapy Trial
February 14, 2024
Medera's Sardocor Announces FDA Clearance of IND for First-in-Human Gene Therapy Clinical Trial for DMD Cardiomyopathy
December 1, 2022
Medera Receives FDA Clearance for a First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction (HFpEF)
November 18, 2022
Sardocor strives to improve the quality of life in patients afflicted with incurable diseases with next-generation cell and gene therapy.
2024 All Rights Reserved | Sardocor, a division of Medera
website design by
boston web partners